Anaptys discontinues ulcerative colitis trial after rosnilimab fails endpoints

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/10/2026

1. META
2. PEP
3. USO
4. SPY
5. WRAP
6. KBH
7. IONS
8. PSA
9. DAL
10. NVDA

Go back to Anaptys discontinues ulcerative colitis trial after rosnilimab fails endpoints
(NASDAQ: ANAB) Delayed: 66.59 --0 (-0%)
Previous Close $66.59    52 Week High $ 
Open $66.59    52 Week Low $ 
Day High $66.59    P/E N/A 
Day Low $66.59    EPS $ 
Volume 1,441